http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0806812-B1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_440b3059c9bcd1d85fd383f9b2ae1b40 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 |
filingDate | 2008-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0c03a2ac905442f762bae9696563f22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6de1b5e331f005b2d4a7020a0514c814 |
publicationDate | 2021-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | BR-PI0806812-B1 |
titleOfInvention | AGENT TO SUPPRESS CHRONIC REJECTION REACTION AND USE OF AN IL-6 INHIBITOR |
abstract | AGENT TO SUPPRESS CHRONIC REJECTION REACTION AND USE OF AN IL-6 INHIBITOR. The present invention relates to the effect of anti-IL-6 receptor antibodies suppressing chronic rejection reaction. The effect of anti-mouse IL-6 receptor antibody (MR16-1) administration on suppression of the chronic rejection reaction was evaluated using a mouse model for chronic rejection after heart transplantation. The result of histopathological analysis of transplanted hearts excised 60 days after transplantation revealed that fibrosis of vascular and myocardial stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the group treated with MR16-1 when compared to control group. Thus, administration of MR16-1 has been shown to have the effect of suppressing chronic rejection reaction. Specifically, the present invention discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody. |
priorityDate | 2007-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 831.